Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. A GROUQ Phase III Randomized Clinical Trial (PCS-VII).

NCT02220829 is registered in ClinicalTrials.gov with Sir Mortimer B. Davis - Jewish General Hospital as lead sponsor.

NCT NCT02220829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02220829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. A GROUQ Phase III Randomized Clinical Trial (PCS-VII).
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2016
Completion date
August 31, 2023
Enrollment
148 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, urinary problems